Document:

<PAGE>

                                                                    EXHIBIT 10.2

"[*]" = confidential portions of this document that have been omitted and have
been separately filed with the Securities and Exchange Commission pursuant to an
application for confidential treatment under Rule 406 of the Securities Act of
1933.

              AGREEMENT REGARDING GOVERNANCE AND COMMERCIAL MATTERS

          This AGREEMENT REGARDING GOVERNANCE AND COMMERCIAL MATTERS (this
"Agreement"), dated December 16, 2001, is entered into by and among American
 ---------
Home Products Corporation, a Delaware corporation ("AHP"), American Cyanamid
                                                    ---
Company, a Maine corporation and wholly owned subsidiary of AHP ("ACC"), and
                                                                  ---
Amgen Inc., a Delaware corporation ("Amgen"), with reference to the following
                                     -----
facts:

                                    RECITALS

          WHEREAS, AHP and ACC are parties to that certain Amended and Restated
Governance Agreement dated as of December 15, 1992, as amended on May 20, 1999,
as further amended August 9, 2000, and as supplemented by that certain Agreement
dated September 23, 1994 between Immunex Corporation, a Washington corporation
("Immunex"), and AHP (collectively, the "Governance Agreement");
  -------                                --------------------

          WHEREAS, the Governance Agreement establishes certain terms and
conditions concerning the corporate governance of Immunex and the disposition of
securities of Immunex by AHP and ACC;

          WHEREAS, Amgen, AMS Acquisition Inc., a Washington corporation and
wholly owned subsidiary of Amgen ("Merger Sub"), and Immunex have entered into
                                   ----------
that certain Agreement and Plan of Merger of even date herewith (the "Merger
                                                                      ------
Agreement") pursuant to which, among other things, Merger Sub shall merge with
---------
and into Immunex (the "Merger") whereupon, at the Effective Time (as defined in
                       ------
the Merger Agreement) of the Merger (the "Effective Time"), Immunex will become
                                          --------------
a wholly owned subsidiary of Amgen;

          WHEREAS, certain terms of the Governance Agreement are implicated by
the Merger Agreement and the transactions contemplated thereby;

          WHEREAS, AHP, ACC and Immunex are parties to that certain Product
Rights Agreement by and among the Wyeth-Ayerst Research division of AHP, the
Lederle Pharmaceutical division of ACC and Immunex dated as of July 1, 1998, as
amended by Amendment No. 1 to the Product Rights Agreement dated May 20, 1999
(the "Product Rights Agreement");
      ------------------------

          WHEREAS, in light of the foregoing and for the avoidance of doubt, AHP
and ACC have agreed to (i) provide for the termination of the Governance
Agreement and (ii) provide for the termination of certain rights under the
Product Rights Agreement; and

          WHEREAS, AHP and Amgen desire to set forth in writing certain other
agreements between them.

                                       1

<PAGE>

                                    AGREEMENT

          NOW THEREFORE, in consideration of the above, the agreements contained
herein, and for other valuable consideration, the receipt and sufficiency of
which are hereby acknowledged, the parties to this Agreement agree as follows:

          1.   Product Rights Agreement.

               a.   No Prior Exercise. AHP and ACC each represents and
acknowledges that, as of the date of this Agreement, AHP has not exercised any
Product Call (as that term is defined in the Product Rights Agreement) under the
Product Rights Agreement. AHP and ACC each hereby agrees that it shall hereafter
provide written notice to Amgen of any Product Call, Replacement Product Call or
Amended ROFR exercised by it at the same time it provides notice to Immunex.

               b.   Termination of Exercise of Product Call. AHP and ACC each
agree that, at the Effectve Time, the exercise of any Product Call, Replacement
Product Call or Amended ROFR (as those terms are defined in the Product Rights
Agreement) which AHP, or any of its subsidiaries or affiliates, initiated or
completed after the execution of this Agreement and prior to the Effective Time
shall terminate as of the Effective Time; provided, that, concurrently with and
as a condition to such termination, Amgen shall pay, or cause Immunex to pay, to
AHP in immediately available funds all amounts paid by AHP to Immunex in
connection with such exercise of any Product Call, Replacement Product Call or
Amended ROFR. Upon such termination, the Product Call, Replacement Product Call
or Amended ROFR right so exercised shall be treated as having never been
exercised and AHP, its subsidiaries or affiliates, shall have no continuing
rights, interests or obligations under any such exercised Product Call,
Replacement Product Call or Amended ROFR or to the product covered by such
Product Call, Replacement Product Call or Amended ROFR. AHP shall promptly
return all information, reports and materials transferred to AHP in conjunction
with such exercise by AHP and cooperate in assigning any third party rights or
agreements relating to the products covered by the exercised Product Call,
Replacement Product Call or Amended ROFR.

               c.   Termination of Rights Under Product Rights Agreement.
Concurrently with the Effective Time, each of AHP, ACC and Amgen shall take all
action necessary to cause the Product Rights Agreement to be amended to provide
that (i) the Amended ROFR Term (as defined in the Product Rights Agreement) and
(ii) the Product Call Term (as defined in the Product Rights Agreement) shall
each be terminated as of the Effective Time; provided, that, concurrently with
and as a condition to such termination, Amgen shall pay, or shall cause Immunex
to pay, a one-time payment of [*] to AHP in exchange for the termination of
the foregoing rights.

          2.   Termination of Governance Agreement. AHP and ACC each hereby
agrees to take any and all action reasonably requested by Amgen to terminate the
Governance Agreement as of the Effective Time.

[*] Confidential Treatment Requested.

                                       2

<PAGE>

          3.   Covenant Not to Sue. Amgen agrees not to sue AHP or its
Affiliates (defined below) under the Amgen Intellectual Property (defined below)
to the sole extent of AHP and its Affiliates developing, having developed,
making, having made, using, having used, marketing, having marketed,
distributing, having distributed, importing, offering for sale, selling and
having sold Enbrel (defined below)(whether alone or in combination or sequential
use with other pharmaceutically active ingredients) anywhere in the world
outside of the United States and Canada. This covenant cannot be assigned or
otherwise transferred to any other person or entity. For the avoidance of doubt,
this covenant shall terminate in the event this Agreement is terminated in
accordance with Section 5 hereof.

               a.   Affiliate. For the purposes of this Section 3 only,
"Affiliate" shall mean any corporation or business entity of which AHP owns
 ---------
directly or indirectly, fifty percent (50%) or more of the assets or outstanding
stock, or any corporation which AHP directly or indirectly controls, or any
parent corporation that owns, directly or indirectly, fifty percent (50%) or
more of the assets or outstanding stock of AHP, or directly or indirectly
controls AHP.

               b.   Amgen Intellectual Property. For the purposes of this
Section 3 only, "Amgen Intellectual Property" shall mean (i) any and all (a)
patents, (b) pending patent applications, including, without limitation, all
provisional applications, substitutions, continuations, continuations-in-part,
divisions, renewals, and all patents granted on any of the foregoing, and (c)
all patents-of-addition, reissues, reexaminations and extensions or restorations
by existing or future extension or restoration mechanisms, including, without
limitation, supplementary protection certificates or the equivalent thereof that
would (if issued) be infringed by the development, manufacture, use or sale of
Enbrel or any pharmaceutical product containing Enbrel, which, in each case is
or are Controlled by or hereafter come into the Control of Amgen.

               c.   Control. For the purposes of this Section 3 only, "Control"
                                                                       -------
or "Controlled" shall mean the possession (whether by ownership  or license,
    ----------
other than pursuant to this Agreement) by Amgen of the ability to grant to AHP
and its Affiliates access and/or a license as provided herein under such item or
right without violating the terms of any agreement or other arrangements with
any third party existing before the date of this Agreement.

               d.   Enbrel. For the purposes of this Section 3 only, "Enbrel"
                                                                    ------
shall mean tumor necrosis factor receptor [*], all derivatives and analogs
thereof (provided however, that such analogs or derivatives shall not include
[*] and any improvements thereto, including, but not limited to, [*].

          4.   Option for Sublicense. Amgen hereby grants to AHP an exclusive
option to acquire, subject to the approval of [*], an exclusive sublicense from
Amgen under that certain License Agreement by and between Amgen and [*] dated
June 18, 1993, such sublicense to be under the terms and conditions of the
sublicense agreement attached hereto as Exhibit A (the "Sublicense Agreement").
No sublicense shall be granted pursuant to this option unless approved by [*],
which

[*] Confidential Treatment Requested.

                                       3

<PAGE>

approval Amgen shall promptly seek at the request of AHP. AHP may exercise such
option at any time on or before December 31, 2002 by providing written notice to
Amgen electing to so exercise such option. In the event AHP so exercises the
option, Amgen and AHP, within ten (10) business days of Amgen's receipt of AHP's
notice, shall execute and deliver to each other the Sublicense Agreement. In the
event AHP exercises its option, in addition to all payments (upfront, milestone
and royalties) due and payable under the Sublicense Agreement, AHP shall pay to
Amgen, a one-time, nonrefundable, noncreditable, reimbursement in an amount not
to exceed [*] for amounts paid to [*] in 2002 to maintain the License Agreement.
Such reimbursement shall be due and payable on the date of execution of the
Sublicense Agreement.

          5.   Effectiveness; Termination. This Agreement will become effective
upon the execution hereof by the parties hereto. This Agreement shall be
terminated and of no further force or effect upon the termination of the Merger
Agreement.

          6.   Third Party Beneficiary. The parties to this Agreement
acknowledge and agree that Immunex shall be an express third party beneficiary
of their respective representations, agreements and obligations under this
Agreement.

          7.   Enforceability. Notwithstanding the fact that Immunex is a party
to the Governance Agreement and the Product Rights Agreement and not a signatory
hereto, this Agreement shall be effective with respect to such agreements and
will be enforceable as it relates to each such Agreement.

          8.   Governing Law. This Agreement shall be governed by the laws of
the State of Delaware without reference to conflicts of laws.

          9.   Amendments, Waivers, Etc. This Agreement may not be amended,
changed, supplemented, waived or otherwise modified or terminated, except upon
the execution and delivery of a written agreement executed by each of Amgen and
AHP. The failure of any party hereto to exercise any right, power or remedy
provided under this Agreement or otherwise available in respect hereof at law or
in equity, or to insist upon compliance by any other party hereto with its
obligations hereunder, and any custom or practice of the parties at variance
with the terms hereof shall not constitute a waiver by such party of its right
to exercise any such or other right, power or remedy or to demand such
compliance.

          10.  Further Assurances. Each party hereto shall execute and deliver
such additional documents and take all such further action as may be necessary
or desirable to comply with and ensure that Amgen and AHP each receive the full
benefit of this Agreement.

          11.  Headings. The headings contained in this Agreement are for
reference purposes only and shall not affect in any way the meaning or
interpretation of this Agreement.

[*] Confidential Treatment Requested.

                                       4

<PAGE>

          12.  Severability. If any term or other provision of this Agreement is
invalid, illegal or incapable of being enforced by any rule of law or public
policy, all other conditions and provisions of this Agreement shall nevertheless
remain in full force and effect so long as the economic or legal substance of
the transactions contemplated hereby is not affected in any manner materially
adverse to any party. Upon such determination that any term or other provision
is invalid, illegal or incapable of being enforced, the parties hereto shall
negotiate in good faith to modify this Agreement so as to effect the original
intent of the parties as closely as possible in an acceptable manner to the end
that transactions contemplated hereby are fulfilled to the extent possible.

          13.  Entire Agreement. This Agreement constitutes the entire agreement
of the parties and supersedes all prior agreements and undertakings, both
written and oral, between the parties, or any of them, with respect to the
subject matter hereof.

          14.  Mutual Drafting. Each party hereto has participated in the
drafting of this Agreement, which each party acknowledges is the result of
extensive negotiations between the parties.

          15.  Counterparts. This Agreement may be executed in one or more
counterparts, and by the different parties hereto in separate counterparts, each
of which when executed shall be deemed to be an original but all of which taken
together shall constitute one and the same agreement.

                            [Signature page follows]

                                       5

<PAGE>

     IN WITNESS HEREOF, the parties have caused this Agreement to be duly
executed by persons duly authorized as of the date first above written.

                                      AMERICAN HOME PRODUCTS CORPORATION

                                             /s/ Kenneth Martin
                                      ----------------------------------
                                      By: Kenneth Martin
                                      Title: Senior Vice President and
                                             Chief Financial Officer

                                      AMERICAN CYANAMID COMPANY

                                             /s/ Kenneth Martin
                                      ----------------------------------
                                      By: Kenneth Martin
                                      Title: Senior Vice President

                                      AMGEN INC.

                                             /s/ Steven M. Odre
                                      ----------------------------------
                                      By: Steven M. Odre
                                      Title: Senior Vice President, General
                                             Counsel and Secretary<PAGE>

                                                                   EXHIBIT 10.34

[LOGO] DAUM                                                     [LOGO] TCN
       Commercial Real Estate Services
                -Since 1904-

December 5, 2001

Mr. Thomas Billstein
Chief Operating Officer
Prolong International Corporation
6 Thomas
Irvine, CA 92618

Re      6 Thomas
        Irvine, California

Dear Tom:

I have been authorized to submit this proposal to purchase the referenced
property at the price, terms and conditions set forth below:

1.      PROPERTY:       6 Thomas, Irvine, California, consisting of an
                        office/industrial building containing approximately
                        29,660 square feet on a land parcel of approximately
                        64,904 square feet.

2.      SELLER:         Prolong Super Lubricants, Inc.

3.      PURCHASER:      Irvine City Financial LLC or Nominee.

4.      PRICE:          $3,675,000.00.

5.      TERMS:          Purchaser shall take Seller's existing loans "subject
                        to" and shall pay the balance of the purchase price in
                        cash. Seller acknowledges Purchaser's intention to
                        reduce the principal balance and extend the due date of
                        the existing third trust deed loan.

6.      ESCROW:         An Escrow shall be established to facilitate the sale of
                        the Property as follows:

        6.1     OPENING OF ESCROW: Upon Seller's acceptance of this offer,
        Escrow Holder shall be instructed to prepare escrow instruction which
        conform to the terms and conditions specified herein. The escrow
        ("Escrow") shall be deemed open when Escrow Holder receives mutually
        executed escrow instructions, and Seller delivers to Purchaser the items
        noted in paragraph 7.2 below.

        6.2     ESCROW HOLDER: First American Title Company, Santa Ana,
        California.

        6.3     ESCROW DEPOSIT: $25,000 deposited in escrow by Purchaser within
        three (3) days of the opening of escrow. Upon Purchaser's approval of
        all conditions as described in Section 7 below, the deposit shall be
        applicable to the sales price at close of escrow, and shall become
        non-refundable except in the event of a default by Seller.

<PAGE>

Mr. Thomas C. Billstein
December 5, 2001
Page 2

7.    CONDITIONS TO PURCHASER'S OBLIGATION TO CLOSE ESCROW:

      7.1 CONTINGENCY PERIOD: Purchaser shall have fourteen (14) days following
      the opening of escrow, or upon Seller's execution of the lease described
      in Paragraph 19 below, whichever occurs last, within which to investigate
      the Property, etc. Purchaser may cancel this agreement during this period
      for any reason or no reason and shall be entitled to the return of the
      deposit.

      7.2 PROPERTY INVESTIGATIONS: As soon as practicable following the mutual
      execution of a Purchase and Sale Agreement, Seller shall deliver to
      Purchaser copies of all leases, operating statements for a minimum of the
      preceding twelve (12) months, plans, parcel maps, most recent Phase One
      environmental report, and other documents in its possession affecting the
      property (Property Documents). Upon Opening of Escrow, Purchaser or
      Purchaser's representatives, employees, lenders and agents shall be
      entitled to enter upon the Property for purposes of inspecting the
      Property and completing any desired studies and analyses concerning the
      Property.

      7.3 TITLE APPROVAL: Promptly after the opening of Escrow, Seller shall, at
      Seller's expense, provide Purchaser with a current preliminary title
      report ("Title Report") delivered by Escrow Holder, showing the status of
      title of the Property together with copies of a11 documents relating to
      title referenced in the Title Report ("Title Documents"). Within the
      Contingency Period, Purchaser shall notify Seller and Escrow Holder in
      writing of any unacceptable exceptions in the Title Report. If Purchaser
      fails during such period to approve or disapprove in writing any
      exceptions shown on the Title Report, Purchaser shall be deemed to have
      approved the Title Report. If Purchaser disapproves of any title matter,
      Seller shall notify Purchaser within three (3) business days whether
      Seller is willing or able to provide for the removal of such title
      matters. If Seller notifies Purchaser that Seller is either unable or
      unwilling to remove the objectionable title matter, Purchaser shall within
      three (3) business days waive its objection or terminate this Agreement.

      7.4 FINANCING CONTINGENCY: None. Purchaser to take Seller's loans "subject
      to." Purchaser to receive and approve all existing notes and trust deeds
      within seven (7) days of receipt.

8.    ESCROW CLOSING DATE: On or before December 31, 2001. However, Purchaser
      shall receive a credit toward the purchase price equal to $750 for each
      day that it closes the escrow prior to December 31, 2001.

9.    TITLE: Seller shall convey fee simple title to the Property, subject
      only to the following: (a) non-delinquent real property taxes, bonds and
      assessments, and (b) exceptions shown in the Title Report approved by
      Purchaser, Seller shall eliminate all other exceptions to title prior to
      the Close of Escrow.

10.   PRORATIONS: Real property taxes and assessments shall be prorated as
      of the Close of Escrow, based on a three hundred sixty (360) day year. The
      amount of any bond or assessment, which is a lien, shall be paid by
      Seller.

<PAGE>

Mr. Thomas C. Billstein
December 5, 2001
Page 3

11.   TITLE INSURANCE POLICY: Escrow shall not close until Escrow Holder is
      prepared to furnish to Purchaser, at Seller's expense, a CLTA policy of
      title insurance showing title vested in Purchaser, subject only to the
      conditions set forth in paragraph 9 above.

12.   CLOSING COSTS: Purchaser shall pay the cost of recording the Grant Deed
      and one-half (l/2) of the Escrow Holder's fee. Seller shall pay one-half
      (l/2) of the Escrow Holder's fee, all of the documentary transfer tax for
      recording the Grant Deed, and the cost of the Title Policy, Escrow Holder
      sha11 notify Purchaser and Seller in writing of their respective shares of
      closing costs no later than three (3) business days prior to the Closing
      Date. If, as a result of Purchaser or Seller, Escrow fails to close,
      Purchaser or Seller shall share equally all of Escrow Holder's fees and
      charges; however, if the transaction fails to close as a result of the
      default of either party, then such defaulting party shall bear all of
      Escrow Holder's fees and charges.

13.   REPRESENTATIONS AND WARRANTIES: Seller represents, warrants and covenants
      to Purchaser that (a) Seller has the right, power, legal capacity and
      authority to execute, deliver and perform this Agreement; (b) all consents
      required as a condition to Seller's authority to execute, deliver and
      perform this Agreement have been obtained; (c) at the time of the
      execution of this Agreement and as of the closing, no leases of the
      Property and no other contracts affecting the Property are or will be in
      force except those disclosed to Purchaser pursuant to paragraph 7.2 above,
      and no one else has a right of possession; (d) after execution of this
      Agreement, Seller shall not enter into any contracts affecting the
      Property without Purchaser's prior written consent; (e) as of the Close of
      Escrow, Seller will have no actual knowledge of any material defect in the
      Property not disclosed in writing to Purchaser; (f) there are not now
      and, as of the Close of Escrow, there will not be any violations of any
      law, ordinance, rule or administrative or judicial order affecting the
      Property; (g) there is no litigation pending respecting the Property.

14.   CONDITIONS OF PROPERTY AT CLOSE OF ESCROW: As is, subject to Purchaser's
      approval of "as is" condition, with the exception of environmental issues
      and those matters addressed herein. In addition, Seller wil1 slurry seal
      and restripe the parking areas and trim all on-site trees by January 31,
      2002.

15.   CONTAMINATION AND HAZARDOUS WASTE: Seller warrants that to the best of its
      knowledge, no hydrocarbon contamination and/or other hazardous waste exist
      at the Subject Property. Seller shall, as its sole cost and expense, order
      a Phase I environmental investigation of the property from a mutually
      approved environmental engineer immediately following the mutual execution
      of the Purchase and Sale Agreement referenced in paragraph 6.1 above.

16.   POSSESSION: Possession shall be delivered to Purchaser at the Close of
      Escrow.

17.   ATTORNEY'S FEES: If either party institutes any action or proceeding to
      enforce any provision of the Agreement through litigation, the prevailing
      party shall be entitled to recover any amounts the court may judge to be
      reasonable attorney's fees from the opposing party.

18.   SUCCESSORS AND ASSIGNS: This Agreement shall be binding upon and shall
      inure to the benefit of the parties hereto, and their respective heirs,
      successors and assigns. Purchaser reserves the right to assign its
      interest in this Agreement to another party or entity, in which

<PAGE>

Mr. Thomas C. Billstein
December 5, 2OO1
Page 4

      event the assuming party or entity shall be bound by all terms and
      conditions of this Agreement.

19.   SELLER LEASE BACK: Seller shall lease the property back from the close at
      escrow, utilizing the A.I.R. Standard Industrial/Commercial Multi-Tenant
      Lease-Net, on the following terms:

      19.1  TERM (GROUND FLOOR): Five (5) years with renewal option of an
      additional five (5) years. Initial lease rate shall be $1.20NNN per square
      foot per month, subject to annual increases equal to three percent (3%).
      The initial lease rate for the renewal term shall be ninety-five percent
      (95%) of fair market value, in no event less than that paid for the
      previous year. Such Lease shall be cancelable by Purchaser at any time
      upon sixty (60) days written notice to Seller.

      19.2  TERM (SECOND FLOOR): Eighteen (18) months, at a monthly rental equal
      to the difference between $30,000 NNN and the rent paid for the ground
      floor. Such lease shall be cancelable by Purchaser at any time upon thirty
      (30) days written notice to Seller.

      19.3  MARKETING OF BUILDING: Seller acknowledges that Purchaser intends to
      market both the second floor alone, as well as the entire building for
      lease following the close of escrow. Any and all costs associated with
      such efforts, including but not limited to leasing commissions and tenant
      improvement costs, shall borne solely by Purchaser.

      19.4  SUBLEASE BY SELLER: In he event Purchaser leases the entry lobby and
      second floor to a third party tenant per Paragraph 19.3 above, and Seller
      subsequently wishes to sublease the ground floor, any sublease rent in
      excess of Seller's lease obligation shall be paid to Purchaser, after
      Seller recoups its actual costs of subleasing, including but not limited
      to subleasing commissions and tenant improvements.

      19.5  DEPOSITS: At the close of escrow, Seller shall pay the first month's
      rent per paragraph 19.1 above, along with a security deposit of
      $90,000.00. $30,000.00 of such security deposit shall be returned to
      Seller following the timely payment of six (6) consecutive months of rent.
      An additional $40,000.00 shall be returned to Seller upon the earlier of
      (a.) Purchaser's lease of entry lobby and second floor to a third party
      tenant per Paragraph 19.3 above, or (b.) the date eighteen (18) months
      following the close of escrow.

20.   REAL ESTATE COMMISSIONS: A real estate sale commission of $135,000.00
      shall be paid to DAUM Commercial Real Estate Services through escrow upon
      closing. Buyer and Seller represent that they have had no dealings with
      any other real estate brokers in connection with this transaction and
      agree to indemnify and hold harmless each other from any claim for
      commissions arising from third parties.

21.   DISCLOSURE: Edwin A. Meserve is a licensed real estate broker in the state
      of California, acting as a principal in this transaction.

<PAGE>

Mr. Thomas C. Billstein
December 5, 2001
Page 5

22.     COOPERATION WITH EXCHANGE:  Seller agrees to cooperate, at no additional
        cost or liability to itself, with the Purchaser to effect & tax-deferred
        exchange in conformance with the requirements of Internal Revenue Code
        Section 1031, should Purchaser so elect.

23.     OFFER:  This offer is subject to the execution of mutually agreeable
        escrow instructions which includes all terms and conditions of this
        proposal.

24.     ACCEPTANCE: This offer is open for acceptance through 5:00 p.m. December
        6, 2001.

We appreciate your consideration of this offer, and look forward to you positive
response.  Please contact me at your earliest convenience should you have any
questions or require additional information.

Very truly yours

/s/ John R. Rothwell
John R. Rothwell
First Vice President

AGREED AND ACCEPTED:

SELLER: Prolong Super Lubricants, Inc.    PURCHASER: Irvine City Financial LLC
                                                      or Nominee

By: /s/ Thomas C. Billstein               By: /s/ Edwin A. Meserve
    -----------------------------------       ----------------------------
                                              Edwin A. Meserve

Date:    12/5/01                          Date:     12/5/01
     ----------------------------------        ---------------------------

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00033-of-00352.parquet"}]]